Tatva Chintan Pharma Chem Ltd

AGM Details

• Date and time: 25 September 2026, 04:00 PM IST, via VC/OAVM.
• End time: 04:53 PM; record date: 18 September 2026.

Resolutions and outcomes

• Resolution 1 (Ordinary): Adoption of standalone financial statements and board report; passed.
• Resolution 2 (Ordinary): Adoption of consolidated financial statements; passed.
• Resolution 3 (Ordinary): Dividend on equity shares for FY ended 31 March 2026; amount not disclosed.
• Resolution 4 (Ordinary): Re-appointment of director retiring by rotation; passed.
• Resolution 5 (Special): Re-appointment of Managing Director with remuneration; passed.
• Resolution 6 (Special): Re-appointment of Whole-time Director with remuneration; passed.
• Resolution 7 (Special): Re-appointment of director for three years; remuneration fixed; passed.
• Resolution 8 (Special): Increase borrowing limit under Section 180(1)(c); passed.
• Resolution 9 (Special): Creation of charge on assets under Section 180(1)(a); passed.
• Resolution 10 (Ordinary): Ratification of Cost Auditor remuneration for FY 2026-27; passed.

AGM Details

• AGM held on 25 September 2026 at 04:00 p.m. IST via VC/OAVM.
• Quorum: 56 members attended via VC/OAVM; meeting lasted until 04:53 p.m. IST.
• Remotely voted on all resolutions; e-voting facility used.

Ordinary Business

• To receive, consider and adopt Audited Standalone Financial Statements for FY ending 31 March 2026.
• To receive, consider and adopt Audited Consolidated Financial Statements for FY ending 31 March 2026.
• To declare dividend on equity shares for FY ended 31 March 2026.
• Re-appointment of Mr. Shekhar Rasiklal Somani, retiring by rotation.

Special Business

• Re-appointment of Chintan Shah as Managing Director for 3 years from 01 Feb 2027; remuneration fixed.
• Re-appointment of Ajaykumar Patel as Whole-time Director for 3 years from 01 Feb 2027; remuneration fixed.
• Re-appointment of Shekhar Rasiklal Somani as Whole-time Director for 3 years from 01 Feb 2027; remuneration fixed.
• Increase in borrowing limit under Section 180(1)(c) of the Companies Act, 2013.
• Creation of charge on assets under Section 180(1)(a) of the Companies Act, 2013.
• Ratification of remuneration payable to the Cost Auditors for the Financial Year 2026-27.

Voting and Outcomes

• Voting was conducted via e-voting; no show-of-hands voting at AGM.
• Results to be disseminated on stock exchanges and company website.
• Scrutinizer appointed to oversee e-voting process.

Tatva Chintan Pharma Chem Limited: Trading Window closed from 01 October 2026 till the completion of 48 hours after the declaration of the Unaudited Financial Results for the quarter and half year ending 30 September 2026.

Meeting Details

• Date: 23 September 2026
• Type: One-to-One Meeting
• Mode: Virtual
• Organiser: Ask Investment Managers Limited
• Purpose: Schedule of Analyst/Financial Institution/Investor meeting

Meeting Details

• Date: 15 September 2026.
• Time: not disclosed.
• Type: One-to-One meeting.
• Mode: Virtual meeting.
• Organiser: HSBC Securities and Capital Pvt. Ltd.

Participants

• Company participant: Chief Financial Officer (CFO).

Purpose

• Purpose: Investor interaction with HSBC for scheduled meeting.

Rating action

• Long-term rating upgraded to CRISIL A-/Stable, from CRISIL BBB+/Stable.
• Short-term rating upgraded to CRISIL A2+, from CRISIL A2; Outlook Stable.
• Total bank loan facilities rated: Rs 245 crore.
• CRISIL maintains ratings under continuous surveillance; can be revised or withdrawn.
• Rating letter valid till March 31, 2027.

Record date and dividend entitlement

• Entitlement to the final dividend for FY 2025-26, subject to AGM approval.
• Applicable to equity shareholders and depository holders.
• Record date: Friday, 11 September 2026.
• Book closure: 12 September 2026 to 25 September 2026 (inclusive).
• 30th AGM on 25 Sep 2026 at 04:00 PM via VC/OAVM.
• Dividend pay-out after 01 October 2026 but within 30 days from AGM.
• E-voting cut-off date: Friday, 18 September 2026.

Filing purpose

• Submit BRSR for FY2025-26; part of the Annual Report; available on the company website.

CSR financials

• CSR turnover: 4,962.96 million; Net worth: 7,582.29 million (FY2025-26).

ESG framework

• Certifications: ISO 9001/14001/45001/22716; TfS; EcoVadis.

GHG & energy

• Scope 1: 10,637.93; Scope 2: 19,479.36 tCO2e; total intensity 0.00000607 per turnover.

Energy & water resources

• Non-renewable energy use: 285,897.23 GJ; water withdrawal: 122,859 kl; water use: 98,937 kl.

Waste management

• Total waste 5,501.98 t; hazardous waste 5,411.69 t; recycled 2,283.05 t; re-used 2,571.72 t.

Sustainability projects

• Sustainability projects: 3.2 MW Wind-Solar at Dahej; 155 kW rooftop solar; Ankleshwar ZLD.

Market footprint

• Exports accounted for 75% of turnover.

Governance

• Board: six members; 16.7% female; KMP female 0%.

Stakeholder engagement

• Engaged with 46 raw material suppliers and 7 customers.

Financial performance

• Standalone revenue ₹4,962.96m; up 35% YoY (FY26).
• Consolidated revenue ₹5,058.58m.
• Consolidated PAT ₹420.54m.
• Consolidated EPS ₹17.98.
• Export revenue share 75.47%.

Dividends & capex

• Final dividend ₹2 per share proposed.
• Capex additions to PPE ₹1,138.43m.

Capex expansion

• New Dahej facility to expand manufacturing capacity.

Debt & liquidity

• Net debt ₹1,155.04m.
• Undrawn facilities ₹1,056.67m.